Education
About Us
Working with TipRanks
Follow Us
Suven Pharmaceuticals Ltd. (IN:SUVENPHAR)
:SUVENPHAR
Total Valuation
Suven Pharmaceuticals Ltd. has a market cap or net worth of ₹384.04B. The enterprise value is ₹170.60B.
Market Cap₹384.04B
Enterprise Value₹170.60B
Share Statistics
Suven Pharmaceuticals Ltd. has 382,567,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding382,567,140
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Suven Pharmaceuticals Ltd.’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 15.57%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.13
Return on Invested Capital (ROIC)15.57%
Return on Capital Employed (ROCE)0.21
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.47
Inventory Turnover1.94
Valuation Ratios
The current PE Ratio of Suven Pharmaceuticals Ltd. is 56.75. Suven Pharmaceuticals Ltd.’s PEG ratio is -2.10.
PE Ratio56.75
PS Ratio0.00
PB Ratio8.31
Price to Fair Value8.31
Price to FCF55.57
Price to Operating Cash Flow47.54
PEG Ratio-2.10
Income Statement
In the last 12 months, Suven Pharmaceuticals Ltd. had revenue of 10.51B and earned 3.00B in profits. Earnings per share was 11.80.
Revenue10.51B
Gross Profit6.01B
Operating Income4.61B
Pretax Income4.06B
Net Income3.00B
EBITDA4.68B
Earnings Per Share (EPS)11.80
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Suven Pharmaceuticals Ltd. pays an annual dividend of ₹1, resulting in a dividend yield of ―
Dividend Per Share₹1
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.77
52-Week Price Change34.41%
50-Day Moving Average1.09K
200-Day Moving Average1.15K
Relative Strength Index (RSI)37.23
Average Volume (3m)6.68K
Important Dates
Suven Pharmaceuticals Ltd. upcoming earnings date is Aug 8, 2025, TBA Not Confirmed.
Last Earnings DateMay 28, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend DateSep 09, 2022
Financial Position
Suven Pharmaceuticals Ltd. as a current ratio of 11.82, with Debt / Equity ratio of 3.17%
Current Ratio11.82
Quick Ratio9.65
Debt to Market Cap<0.01
Net Debt to EBITDA0.04
Interest Coverage Ratio61.84
Taxes
In the past 12 months, Suven Pharmaceuticals Ltd. has paid 1.05B in taxes.
Income Tax1.05B
Effective Tax Rate0.26
Enterprise Valuation
Suven Pharmaceuticals Ltd. EV to EBITDA ratio is 36.47, with an EV/FCF ratio of 55.62.
EV to Sales16.23
EV to EBITDA36.47
EV to Free Cash Flow55.62
EV to Operating Cash Flow47.59
Balance Sheet
Suven Pharmaceuticals Ltd. has ₹6.56B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹6.56B billion.
Cash & Marketable Securities₹6.56B
Total Debt₹0.00
Net Cash-₹6.56B
Net Cash Per Share-₹17.14
Tangible Book Value Per Share₹78.15
Margins
Gross margin is 57.34%, with operating margin of 43.83%, and net profit margin of 28.56%.
Gross Margin57.34%
Operating Margin43.83%
Pretax Margin38.59%
Net Profit Margin28.56%
EBITDA Margin44.49%
EBIT Margin39.29%
Analyst Forecast
The average price target for Suven Pharmaceuticals Ltd. is ₹1,416.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target₹1,416.67
Price Target Upside27.89% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―